Sea4Pain approved for funding under the SME Instrument – Phase 1

Posted on

Project approved for funding under the SME Instrument - Phase 1

On March 23rd, 2018, our project, Sea4Pain, was approved for funding under the SME Instrument - Phase 1!

Title of project
"Development of a novel analgesic for chronic pain from marine-derived compounds"

Acronym
"Sea4Pain"

Abstract
The project now approved aims to define the development strategy of Sea4Us platform for the discovery and development of new drugs of marine origin (Portuguese). In particular, regarding the project to develop a new analgesic for moderate to severe chronic pain of high efficacy, with reduced toxicity and limited side effects, giving rise to a new class of drugs.
The Sea4Pain project will allow defining the next steps in drug development, including clinical trials. To this end, Sea4Us will establish new partnerships, update the business plan and prepare the next phases of investment.

Chronic pain
Currently, 21% of the world's population suffers from chronic pain and the Sea4Pain project will contribute to the development of alternative treatments for patients suffering from moderate to severe chronic pain. Medications currently on the market (opioid derivatives and others) relieve pain, but they co-inflict many adverse side effects (including habituation and addiction) and great loss of quality of life.